Business Description
Compare
Compare
Traded in other countries / regions
0VY.GermanyIMAB.USA IPO Date
2020-01-17Description
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 37.77 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -0.61 | |||||
| Beneish M-Score | 2.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.3 | |||||
| 3-Year EBITDA Growth Rate | -56.1 | |||||
| 3-Year EPS without NRI Growth Rate | -32.8 | |||||
| 3-Year FCF Growth Rate | -29.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.24 | |||||
| 9-Day RSI | 21.16 | |||||
| 14-Day RSI | 27.12 | |||||
| 6-1 Month Momentum % | -8.24 | |||||
| 12-1 Month Momentum % | -76.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.31 | |||||
| Quick Ratio | 7.31 | |||||
| Cash Ratio | 6.65 | |||||
| Days Inventory | 137.41 | |||||
| Days Sales Outstanding | 51.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 39.5 | |||||
| Operating Margin % | -1511.75 | |||||
| Net Margin % | -1882.23 | |||||
| ROE % | -48.96 | |||||
| ROA % | -41.06 | |||||
| ROIC % | -218.68 | |||||
| ROC (Joel Greenblatt) % | -1653.18 | |||||
| ROCE % | -42.42 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 13.45 | |||||
| PB Ratio | 0.43 | |||||
| Price-to-Tangible-Book | 0.47 | |||||
| EV-to-EBIT | 0.92 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | 0.94 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-Revenue | -15.97 | |||||
| EV-to-Forward-Revenue | 0.23 | |||||
| EV-to-FCF | 1.72 | |||||
| Price-to-Net-Current-Asset-Value | 0.52 | |||||
| Price-to-Net-Cash | 0.59 | |||||
| Earnings Yield (Greenblatt) % | 108.7 |
How I-MAB (IMAB) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMAB
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
I-MAB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 18.776 | ||
| EPS (TTM) ($) | -4.42 | ||
| Beta | 1.09 | ||
| Volatility % | 94.96 | ||
| 14-Day RSI | 27.12 | ||
| 14-Day ATR ($) | 0.323249 | ||
| 20-Day SMA ($) | 3.779 | ||
| 12-1 Month Momentum % | -76.22 | ||
| 52-Week Range ($) | 2.73 - 21.44 | ||
| Shares Outstanding (Mil) | 83.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
I-MAB Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
I-MAB Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
I-MAB Frequently Asked Questions
What is I-MAB(IMAB)'s stock price today?
The current price of IMAB is $3.14. The 52 week high of IMAB is $21.44 and 52 week low is $2.73.
When is next earnings date of I-MAB(IMAB)?
The next earnings date of I-MAB(IMAB) is 2023-03-29 Est..
Does I-MAB(IMAB) pay dividends? If so, how much?
I-MAB(IMAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
